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A Prospective, Multicenter, Phase I Matched-Comparison
Group Trial of Safety, Pharmacokinetics,
and Preliminary Efficacy of Riluzole in Patients
with Traumatic Spinal Cord Injury
Robert G. Grossman,1,* Michael G. Fehlings,2,* Ralph F. Frankowski,3 Keith D. Burau,3 Diana S.L. Chow,4
Charles Tator,2 Angela Teng,4 Elizabeth G. Toups,1 James S. Harrop,5 Bizhan Aarabi,6 Christopher I. Shaffrey,7
Michele M. Johnson,8 Susan J. Harkema,9 Maxwell Boakye,9 James D. Guest,10 and Jefferson R. Wilson2
Abstract
A prospective, multicenter phase I trial was undertaken by the North American Clinical Trials Network (NACTN) to
investigate the pharmacokinetics and safety of, as well as obtain pilot data on, the effects of riluzole on neurological
outcome in acute spinal cord injury (SCI). Thirty-six patients, with ASIA impairment grades A–C (28 cervical and 8
thoracic) were enrolled at 6 NACTN sites between April 2010 and June 2011. Patients received 50 mg of riluzole PO/NG
twice-daily, within 12 h of SCI, for 14 days. Peak and trough plasma concentrations were quantified on days 3 and 14.
Peak plasma concentration (Cmax) and systemic exposure to riluzole varied significantly between patients. On the same
dose basis, Cmax did not reach levels comparable to those in patients with amyotrophic lateral sclerosis. Riluzole plasma
levels were significantly higher on day 3 than on day 14, resulting from a lower clearance and a smaller volume of
distribution on day 3. Rates of medical complications, adverse events, and progression of neurological status were
evaluated by comparison with matched patients in the NACTN SCI Registry. Medical complications in riluzole-treated
patients occurred with incidences similar to those in patients in the comparison group. Mild-to-moderate increase in liver
enzyme and bilirubin levels were found in 14–70% of patients for different enzymes. Three patients had borderline severe
elevations of enzymes. No patient had elevated bilirubin on day 14 of administration of riluzole. There were no serious
adverse events related to riluzole and no deaths. The mean motor score of 24 cervical injury riluzole-treated patients
gained 31.2 points from admission to 90 days, compared to 15.7 points for 26 registry patients, a 15.5-point difference
( p = 0.021). Patients with cervical injuries treated with riluzole had more-robust conversions of impairment grades to
higher grades than the comparison group.
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Introduction
There is currently no neuroprotective therapy thathas emerged as a standard of care after traumatic spinal cord
injury (SCI). After a traumatic injury, the spinal cord undergoes a
prolonged series of biological processes of reaction and repair.
Therapies have been directed toward limiting the damage to the
spinal cord and enhancing repair at each stage of the process. The
general categories of therapy have been neuroprotection to limit
the secondary injury that occurs after acute trauma, modulating the
inflammatory response to injury, modifying the glial and fibro-
blastic scar that blocks regrowth of axons, and stimulating regrowth
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and repair of damaged axons and providing substrates to guide
axons and bridge gaps. Substantial repair of SCI will probably
require the application of a series of therapies, each directed toward
a particular phase of the reactive and reparative processes.
Early within the secondary injury cascade, the initial trauma
force, in combination with subsequent ischemic changes, leads to
neuronal membrane dysfunction, which includes the constitutive
activation of voltage-gated sodium ion channels.1–3 This pathologic
continuous activation causes a marked increase in intracellular
sodium levels and leads to an influx of calcium ions through the
sodium-calcium exchange pump.4,5 Rises in intracellular calcium
concentration then lead to the extracellular release of toxic levels
of the excitatory neurotransmitter glutamate.6 The combination of
these events leads to increased regional cellular death as a result of
ionic imbalance, formation of reactive oxidative ions, intracellu-
lar energy failure, cytotoxic edema formation, and glutamatergic
excitotoxicity.
Riluzole, a sodium-channel blocking medication, which is U.S.
Food and Drug Administration (FDA) approved for the treatment of
amyotrophic lateral sclerosis (ALS),7 has been shown to improve
the outcome of SCI in preclinical studies.8,9 Twelve preclinical
studies of riluzole efficacy in acute rodent models of SCI, published
between 1996 and 2011, have recently been summarized in a re-
view article on neuroprotective drug therapy and SCI.10 In com-
parison to control animals, riluzole-treated animals exhibited
reduced tissue cavitation and better preservation of white matter,
motor neurons, mitochondrial function, somatosensory-evoked
potentials, and locomotor scores in different studies.10 Recent work
evaluating the timing of riluzole administration in rats revealed that
treatment initiated at both 1 and 3 h postinjury resulted in improved
neurobehavioral outcomes as well as tissue-preserving effects.11
The presence of a well-defined target mechanism and demonstra-
tion of beneficial effects in pre-clinical studies, combined with its
tolerability in the ALS population, make riluzole an attractive
candidate for evaluation to treat acute human SCI.12 With this
background, a phase I prospective, matched-comparison group trial
of the pharmacokinetics (PK), safety, and preliminary efficacy of
riluzole as a neuroprotective agent in acute traumatic SCI was
carried out with the following goals to:
1. Test the feasibility of a trial of a therapy that must be ad-
ministered within 12 h of acute traumatic SCI.
2. Study the PK and pharmacodynamics of riluzole in SCI.
3. Obtain data on the safety of riluzole in SCI using a matched
cohort group for comparison.
4. Obtain exploratory pilot data on the effects of riluzole on
measures of neurological outcome after SCI using a matched
cohort group for comparison.
5. Relate the pharmacology of riluzole in SCI to safety and
outcome measures.
Methods
Organization of the trial by the North American Clinical
Trials Network
The trial was registered with ClinicalTrials.gov (identifier:
NCT00876889). Planned enrollment of 36 patients was conducted
between April 12, 2010 and June 20, 2011 at six clinical centers of
the North American Clinical Trials Network (NACTN) for Treat-
ment of Spinal Cord Injury (Table 1). NACTN is a consortium of
clinical centers composed of neurosurgery department faculty and
staff caring for SCI patients at university-affiliated hospitals, a
coordinating center, a data management center and a pharmaco-
logical center. Each NACTN clinical center has one or two prin-
cipal investigators and a study coordinator who is a physician or a
clinical research nurse. NACTN was established in 2005 with the
support of the Christopher Reeve Foundation, which is its spon-
soring organization.13,14 The Telemedicine and Advanced Tech-
nology Research Center (TATRC), United States Army Medical
Research and Materiel Command (USAMRMC), has supported
NACTN since 2006. Partial grant support for this trial was also
received from AOSpine, which helped to facilitate the trial design
and initial logistics of trial implementation.
Trial design: Riluzole treatment cohort and eligibility
criteria
The trial was a multi-site, single-arm, open-label-treatment pilot
study with an enrollment goal of 36 patients. Eligibility criteria are
given in Table 2. A detailed description of the trial design has been
Table 1. Trial Sites
Trial sites Principal investigators
Thomas Jefferson University,
Philadelphia
James S. Harrop, MD
University of Maryland,
Baltimore
Bizhan Aarabi, MD
University of Virginia,
Charlottesville
Christopher I. Shaffrey, MD
University of Texas Health
Science Center, Houston
Michele M. Johnson, MD
University of Louisville,
Louisville
Susan J. Harkema, PhD
Maxwell Boakye, MD
University of Toronto,
Toronto
Michael G. Fehlings, MD, PhD
Charles H. Tator, MD, PhD
Table 2. Eligibility Criteria
Inclusion criteria
Age ‡ 18 and £ 70 years
Written informed consent by patient or legally authorized
representative to participate in the study
No other life-threatening injury
Nonpenetrating spinal cord injury at neurologic level from C4 to
T11
ASIA Impairment Scale grade A, B, or C
No cognitive impairment that would preclude an informed
consent, including moderate or severe traumatic brain injury
Initial dose of riluzole within 12 h of injury
Exclusion criteria
Hypersensitivity to riluzole or any of its components
Unable to receive riluzole orally or by nasogastric tube
History of liver or kidney disease (e.g., hepatitis A, B, or C
or cirrhosis)
A recent history of regular substance abuse (illicit drugs
or alcohol)
Unconscious
Penetrating spinal cord injury
Pregnancy as established by urine pregnancy test
Currently involved in another spinal cord injury research study
Has a mental disorder or other illness, which, in the view of the
site investigator, would preclude accurate medical and neuro-
logical evaluation
Unable to commit to the follow-up schedule
Is a prisoner
Unable to converse, read, and write in English at the elementary-
school level
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published previously.15 The sample size of this safety study was
established in advance and was based on complication rates ob-
served in NACTN registry data13 and discussed below. The inci-
dence rates of complications were expected to range from 0.15 to
0.30 in patients not treated with riluzole. Using a one-sided exact
binomial test with a type I error rate of 5%, a case series of 36
patients receiving riluzole was projected to have approximate
power of 0.80–0.99 to detect doubling of the complication rate in
the riluzole case series.
Comparison group: North American Clinical Trials
Network Spinal Cord Injury Registry group
As a phase I trial, the study did not have a concurrent control
group of patients who did not receive riluzole, but who otherwise
received the same standard of care treatment as the riluzole cohort.
In lieu of a concurrent control group with which to compare the
safety and neurological outcome data for the riluzole cohort, a
comparison group was formed of 36 SCI patients who had received
standard-of-care treatment at the NACTN clinical centers, whose
records were in the NACTN SCI Registry. The NACTN SCI
Registry contains information about the clinical courses of 594 SCI
patients admitted to the NACTN clinical centers from October
2005 through November 2012, who consented to having data on
their injury recorded in an institutional review board (IRB)- and
human research protection office (HRPO)-approved data registry.
Information was collected prospectively under the following
headings: demographic data; medical history; initial clinical status;
Glasgow Coma Score (GCS); Abbreviated Injury Score; Interna-
tional Standards For Neurological Classification of Spinal Cord
Injury (ISNCSCI) motor, sensory, and impairment scores; type of
neurological injury; type of bony injury; imaging of cord and canal
diameters on computed tomography, magnetic resonance imaging,
or myelogram; traction-reduction; medical therapy; surgical ther-
apy; complications, including cardiac, pulmonary, hematological,
gastrointestinal (GI), genitourinary (GU); infectious; skin; and
neuropsychiatric.14
Data from 36 registry patients meeting the eligibility criteria for
the riluzole patients were matched with the 36 patients treated with
riluzole. Criteria for registry cases included admission to a NACTN
center within 12 h of injury, American Spinal Injury Association
(ASIA) Impairment Scale (AIS) grade A, B, or C at admission,
cervical or thoracic injury, nonpenetrating SCI at neurological level
from C4 to C11, and GCS > 13. Registry cervical and thoracic
cases were then matched by AIS grade to the riluzole patients’
neurological level of injury, gender, and age. This hierarchy of
matching was the method adopted to select among multiple mat-
ches. All matching was blinded to outcome measures in the registry
and riluzole groups. Thirty (83%) of the 36 registry patients were
drawn from five of the six NACTN sites trialing riluzole in the
present study.
Determination of riluzole dose and dosing schedule
Riluzole (50 mg; Rilutek; Sanofi-Aventis, Bridgewater, NJ)
was administered every 12 h orally or by nasogastric tube, starting
within 12 h of injury for 28 doses.
The riluzole dose was determined by using human data and by
scaling from animal data.16 From the human data, the most con-
servative approach was used, based on the FDA-approved dose for
ALS patients. In dose-ranging studies of riluzole in ALS that used
doses of 50, 100, and 200 mg/day, a daily dose of 50 mg twice-daily
(b.i.d.) of riluzole was confirmed to have the best benefit-to-risk
ratio.17
From animal data, the human equivalent dose (HED) was allo-
metrically scaled from the animal dose (6 mg/kg b.i.d.) in female
Wistar rats (weight, 250–300 g) and was calculated with the
equation from FDA Guidance for Industry (2005)18:
HED¼Animal Dose (mg=kg) · (animal wt=human wt in kg)0:33
¼ (6 mg=kg bid) · (0:25 kg=70kg)0:33
¼ 0:92 mg=kg bid¼ 64:2 mg=70 kg b:i:d:
The trial dose of 50 mg b.i.d. was set conservatively below the HED
of 64.2 mg b.i.d., scaled from the effective, safe animal dose of
6 mg/kg b.i.d.11 and in concordance with the dose of 50 mg b.i.d.
that achieved the best safety and efficacy balance in ALS patients.17
The time window of 12 h after injury for administration of ri-
luzole is in concordance with a study of delayed postinjury ad-
ministration of riluzole in a preclinical model of moderate cervical
SCI.11 Riluzole treatment at 1 h and at 3 h postinjury both provided
locomotor improvement. Differences in metabolic rate and time
course of appearance of inflammatory biomarkers in rodents and
humans suggest that pathological changes in SCI peak 4–6 times
more rapidly in rat than in human SCI, making 12 h a reasonable
exploratory time window for a phase I trial of riluzole.11 The mean
time and standard deviation (SD) of SCI patients receiving the first
dose of riluzole in the present study was 8.7 – 2.2 h.
Pharmacology of riluzole in spinal cord injury patients
The PK of riluzole in the 36 patients in the present study have
been published in detail.16 Plasma samples for PK study were
collected 1–2 h predose and 2 h postdose for trough and peak
concentrations, respectively, on days 3 and 14 after the initial dose.
Findings that are pertinent to the phase I clinical trial are given
below in the Results section of this report.
Patient care protocol
Patients received care for SCI as described in the Guidelines
for the Management of Acute Cervical Spine and Spinal Cord
Injuries.19 Treatment included rapid ventilatory, cardiovascular and
nutritional support, reduction of vertebral subluxations, surgical
decompression of the spinal cord and vertebral stabilization, and
prophylactic measures to prevent deep vein thrombosis (DVT)
using leg compression devices and/or anticoagulation with heparin
or low molecular weight heparin. Administration of corticosteroids,
generally methylprednisolone (MPSS), was in accord with the
policies of the admitting center. Thirty–nine percent of the riluzole
and 58% of the registry patients received MPSS.
Schedule of events and data collection
Table 3 shows the schedule of events for the study, the riluzole
dosing schedule, and the clinical and laboratory data that were
collected on admission to the study, during acute hospitalization,
and at 42– 7, 90– 10, and 180– 14 days.
Screening and admission to the study
SCI patients examined in the emergency department (ED) within
12 h of injury were screened for eligibility and had the study ex-
plained to them and to legally authorized representatives, if present.
Consenting individuals were then enrolled in the trial. Time of
enrollment was taken as the time of admission to the study, and the
measurements referred to in the tables as admission data were made
at this time, before receiving riluzole. For the purpose of recording
and tracking riluzole administration, the day on which the first dose
of riluzole was given was designated as day 1 of the study.
Data collection
Data were collected prospectively, daily when required by the
protocol, by NACTN clinical coordinators working together with
the principal investigators of each clinical site. Data were recorded
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on 16 case-report forms, throughout the course of the acute care
hospitalization of the patients and at the follow-up visits made in
the rehabilitation hospital or at the clinical center. The following
data were collected:
1. Prehospitalization demographic data, past medical history,
preinjury medication use, circumstances and time of injury,
and time of arrival to the ED of the admitting NACTN
hospital.
2. Evaluation of the medical condition of the patient.
3. Measurement of neurological status with ISNCSCI motor
and sensory and AIS examinations.20 Evaluations were re-
peated on days 3 and 14 of acute hospitalization, before and
after spinal surgery, and at the 42-, 90-, and 180-day ex-
aminations. The Spinal Cord Independence Measure
(SCIM)21 was performed at 90 and 180 days.
4. Details of the medical and surgical therapy received.
5. Hematology and blood chemistries, including liver function
tests, were drawn on admission to the study and on days 3, 7,
10, and 14 and when medically indicated at 42, 90, and 180
days.
6. Medical complications and serious adverse events (SAEs)
were assessed by NACTN principal investigators by obser-
vation of the patients with input of the clinical coordinators
as well as medical and nursing staff. Categorization and
severity level of complications were determined by the
principal investigators using the criteria described in an
analysis of the incidence and severity of acute complications
after SCI, based on data from the NACTN SCI Registry.22
All data were submitted to the data management center and were
subjected to multiple manual and electronic data quality-control
procedures.
Compliance with regulatory requirements
1. Approval of the protocol by the HRPO of the Department of
Defense (DoD).
2. Harmonization of the IRB requirements of each center with
requirements of the HRPO; final approval of the harmonized
protocol and the informed consent form by each IRB.
3. Appointment of a central trial medical monitor, a physiatrist
at a university unaffiliated with any of the centers, who re-
ceived reports of all SAEs.
4. Appointment of a local medical monitor at each clinical
center who received reports of adverse events at that center.
Training of personnel and trial initiation meeting
Two training meetings were held at the Frazier Rehab Institute
for the principal investigators and study coordinators, reviewing in
detail the study protocol, the Guidelines for the Management of
Acute Cervical Spine and Spinal Cord Injuries19 and in performing
ASIA examinations on individuals with SCI under the guidance of
skilled instructors.
A trial initiation meeting of all investigators and coordinators
was held at The Methodist Hospital Coordinating Center, including
a 2-day review of the protocol, the schedule of events, the rules and
procedures for reporting adverse events, and stopping rules.
Site monitoring
NACTN’s study monitor conducted on-site visits to the clinical
centers and reviewed case report forms, source documentation, and
on-site regulatory binders to ensure regulatory and protocol com-
pliance with Good Clinical Practices.
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Statistical analysis
Admission characteristics of riluzole and registry patients were
compared using two-sample independent t-tests and two-sample
chi-square methods or Fisher’s exact test, as appropriate, for cat-
egorical data. Chi-square methods were also used to compare the
incidence of medical complications between the two groups. Total
motor scores for riluzole and registry patients stratified by im-
pairment grade at admission were analyzed using the permutation
test for independent samples, with motor scores as the raw obser-
vations. The permutation test makes no assumptions about the
shapes of the underlying distributions or dispersions of motor
scores and is particularly effective for skewed data. Permutation
tests were computed using StatXact 8 with Cytel Studio software
(Cytel Inc., Cambridge, MA).
Box plots were used to compare distributions of 90- and 180-day
gains in total motor score and pin-prick sensory scores for the
riluzole and registry groups. Box plots show the middle 50% of the
data by a box that extends from the 25th to the 75th percentile and
tails (whiskers) that contain at least 99% of the data and markers
that indicate any outlying data values. Sample medians are shown
within each box. Box plots are labeled for ease in interpretation and
comparison. All graphics and other statistical tests were computed
using StatCorp (2009) Stata statistical software (Release 11; Sta-
taCorp LP, College Station, TX).
Results
The enrollment goal of the study was fulfilled. Thirty-six pa-
tients with acute traumatic injury to the spinal cord (ages, 18–69),
FIG. 1. Patient flow diagram of numbers of riluzole and registry patients available with complete motor scores on admission and at 42,
90, and 180 days.
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impairment grades A–C, with levels of injury (lowest normal motor
level) C4-T11, were enrolled at six NACTN clinical center hos-
pitals between April 12, 2010 and June 20, 2011 and received
riluzole enterally within 12 h of injury at a dose of 50 mg every 12 h
for a total of 28 doses.
Cervical and thoracic injuries—riluzole and registry
cohorts: Impairment grade on admission, demographics,
cause of injury, hours to admission to emergency
department and surgery, and corticosteroid
administration
Figure 1 provides an overview of patient flow for safety and
neurological outcome data, stratified by cervical and thoracic sites
of injury and impairment grade. There were no statistically sig-
nificant differences in demographics or clinical variables for the
riluzole and registry patient groups (Table 4). Table 4 shows that
28 (78%) injuries in the riluzole cohort were cervical and 8 (22%)
were thoracic.
Patients in the registry cohort were selected to match the num-
bers of cervical and thoracic injuries, neurological levels of injury,
and impairment scale grades of the patients in the riluzole cohort.
Distribution of impairment grades for both the riluzole and the
registry cohorts was 19A, 9B, and 8C. Thirty (83%) patients were
male and 6 (17%) were female in the riluzole cohort. The gender
ratio was nearly identical in the registry cohort. The mean age was
41.3 years for patients with cervical injuries and 45.4 for patients
with thoracic injuries, with a range of 18–69 in the riluzole cohort.
The mean age for the cervical injuries in the registry cohort was
40.8 years. The causes of injury were predominantly motor vehicle
accidents (N = 20) and falls (N = 9) in the riluzole cohort; the causes
in the registry cohort were similar. Mean hours from injury to ED
were 3.0 – 1.8 for riluzole patients with cervical injuries and
2.5 – 2.3 for registry patients.
Table 4. Cervical and Thoracic Injuries: Demographics and Clinical Variables on Admission
To Study in Riluzole and Registry Patients
Riluzole Registry Riluzole Registry
Variable Cervical N = 28 Cervical N = 28 p value Thoracic N = 8 Thoracic N = 8
AIS
A 12 12 7 7
B 8 8 1 1
C 8 8 0 0
Total 28 28 Matched 8 8
Age in years 41.3 – 17.4 40.8 – 14.4 0.91 45.4 – 16.4 30.4 – 17.7
Gender
Male 24 23 6 8
Female 4 5 2 0
Total 28 28 1.00 8 8
Cause
Motor vehicle accident 13 8 7 6
Fall 8 11 1 2
Sports 5 8 0 0
Assault 2 1 0 0
Total 28 28 0.52 8 8
Hours to hospital ED 3.0 – 1.8 2.4 – 2.3 0.28 3.6 – 1.7 2.7 – 2.9
Surgery
Yes 25 28 8 8
No 3 0 0 0
Total 28 28 0.24 8 8
Hours to surgery
6–12 14 11 1 2
12–24 7 9 3 2
24–48 3 3 4 3
> 48 1 5 0 1
Total 25 28 0.42 8 8
Body mass index 26.4 – 4.1 27.0 – 4.2 0.59 28.1 – 4.3 26.1 – 1.9
Surgical approach
Anterior 4 7 0 1
Posterior 7 10 5 7
Both 14 11 3 0
Total 25 28 0.52 8 8
Corticosteroids
Yes 10 17 4 4
No 18 11 4 4
Total 28 28 0.11 8 8
AIS, American Spinal Injury Association Impairment Scale; ED, emergency department.
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Thirty-three (92%) of the riluzole patients underwent early
surgery for spinal cord decompression and vertebral column
stabilization, 42% within 6–12 h of injury, and another 28% in
12–24 h. Three of the cervical injuries did not undergo surgery.
Median hours from injury to surgical decompression and stabi-
lization were 11.3 h for cervical injuries and 23.6 for thoracic
injuries for the riluzole cohort and were similar for the registry
cohort. Surgical approaches were anterior (4; 12%), posterior (12;
36%), and both (17; 51%) for the riluzole cohort and were similar
for the registry group.
Corticosteroids were administered at the time of admission to
39% of the riluzole cohort and 58% of the registry group.
The mean duration of initial hospitalization of the riluzole cohort
was 17 days (range, 5–41). Thirty-five patients were discharged to a
rehabilitation hospital and 1 to a nursing facility. The mean dura-
tion of hospitalization for the registry cohort was 23 days.
The leading pre-existing medical conditions in the riluzole co-
hort were hypertension (10 patients) and diabetes mellitus (5 pa-
tients) and were similar in the registry cohort.
Neurological levels of injury for cervical and thoracic patients
receiving riluzole and for registry patients are shown in Table 5.
For the patients with cervical injuries in the riluzole cohort,
C4-level injuries predominated (N = 13; 46% of cervical in-
juries), followed by C5 and C6 (N = 7; 25% each) and C8 (N = 1;
4%). Among the thoracic injuries, 4 (50%) were high thoracic,
at T1 and T2, respectively, 2 (25%) were mid-thoracic, at T6
and T9, and 2 were low thoracic, at T11. Seven of the eight
thoracic injuries were impairment grade A on admission and
one was B. Levels of injury were similar for riluzole and reg-
istry patients.
Distribution of impairment grades on admission for each level of
injury for patients receiving riluzole is shown in Table 6. Dis-
tribution was similar for registry patients.
Time to riluzole administration and number
of doses received
The mean time to the first dose of riluzole was 8.7 h for the
riluzole cohort (n= 36) as a whole (Table 7). Thirty-five patients
completed the study. The goal of administering 28 doses of riluzole
was reached in 71% of these 35 patients; an additional 26% re-
ceived 27 doses and 3% received 26 doses.
Patient withdrawal
One patient was withdrawn on the seventh day of receiving
riluzole when his liver function tests showed a moderate elevation
of gamma-glutamyl transpeptidase (GGT). This patient was a
69-year-old man with previous comorbidities of emphysema and
hypertension. He had sustained a C4 injury in a fall (impairment
grade C). He developed respiratory failure on day 2 and pneumonia
on day 4. GGT was normal on admission and on day 4, but had risen
to 4.6 · the upper limit of normal (ULN) on day 7. He was receiving
medications that can impair liver function. Riluzole was stopped as
a precautionary measure to prevent possible liver damage. GGT fell
to a mildly elevated level on day 10. Impairment grade was C at 90
days postinjury and GGT was normal.
Pharmacokinetics of riluzole in spinal cord injury
patients
A detailed report of the PK of riluzole in the patients in this study
has been published.16 The following will summarize the key data
that are of pertinence to the current report. Riluzole PK were
evaluated in 33 patients on day 3 and in 32 patients on day 14, as
Table 5. Cervical and Thoracic Injuries: Riluzole
and Registry Patients: Neurological Levels of Injury
Level of injury N (%) % of cervical
Riluzole cervical N = 28
C4 13 (36.1) 46.4
C5 7 (19.4) 25.0
C6 7 (19.4) 25.0
C8 1 (2.8) 3.6
Total cervical 28 (77.8) (100)
Level of injury N (%) % of thoracic
Riluzole thoracic N = 8
T1 2 (5.6) 25.0
T2 2 (5.6) 25.0
T6 1 (2.8) 12.5
T9 1 (2.8) 12.5
T11 2 (5.5) 25.0
Total thoracic 8 (22.2) (100)
Total cervical and thoracic 36 (100)
Level of injury N (%) % of cervical
Registry cervical N = 28
C4 11 (30.6) 39.3
C5 10 (27.8) 35.7
C6 6 (16.7) 21.4
C8 1 (2.8) 3.6
Total cervical 28 (77.8) (100)
Level of injury N (%) % of thoracic
Registry thoracic N = 8
T1 3 (8.3) 37.5
T6 2 (5.5) 25.0
T10 1 (2.8) 12.5
T11 1 (2.8) 12.5
T12 1 (5.5) 12.5
Total thoracic 8 (22.2) (100)
Total cervical and thoracic 36 (100)
Table 6. Cervical Injuries: Riluzole and Registry
Patients: Neurological Level and Distribution
of Impairment Grades on Admission
Level A B C Total
Riluzole: impairment grade
C4 5 4 4 13
C5 2 3 2 7
C6 4 1 2 7
C8 1 0 0 1
Total 12 8 8 28
Registry: impairment grade
C4 5 4 2 11
C5 2 3 5 10
C6 4 1 1 6
C8 1 0 0 1
Total 12 8 8 28
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both Cpeak and Ctrough samples of patients were collected and
quantifiable. The plasma concentration and the systemic exposure
to riluzole (area under the plasma-concentration curve; AUC0–12)
varied significantly among patients. Maximum concentration
(Cmax) ranged from 24 to 409 ng/mL (mean, 129 – 14; standard
error [SE]) on days 3 and 9 to 317 ng/mL (mean, 77 – 14; SE) on
day 14.
The PK of riluzole—Cmax, Cmin, AUC0–12, clearance (CL), and
volume of distribution (V)—changed during the acute and subacute
phases of SCI during the 14 days of administration, a phenomenon
consistently observed in all patients at all clinical sites. Mean Cmax,
Cmin, and AUC0–12 (129 ng/mL, 46 ng/mL, and 982 ng*h/mL, re-
spectively) were significantly higher on day 3 than on day 14
(77 ng/mL, 19 ng/mL, and 521 ng*h/mL, respectively), resulting
from lower CL (50 vs. 106 L/h) and a smaller V (557 vs. 1298 L) on
day 3.16
Safety: Medical complications and serious adverse
events
SCI patients have a high incidence of physiological disturbances
and medical complications occurring acutely after injury as docu-
mented in a recent publication of data from the NACTN SCI
Registry.22 Using the definitions of severe and moderate compli-
cations described in that article, the incidence of complications
occurring within 30 days of injury was determined. Table 8 shows
medical complications and SAEs tabulated both by frequency of
occurrence of specific types of complications (e.g., infection and
pulmonary) and by the number of individuals sustaining one or
more complication. Complications reported as SAEs are marked
with a superscript b.
Table 9 shows the number of patients in the riluzole and registry
groups who sustained at least 1 complication involving one or more
of the seven organs or systems by which complications were
classified and the incidences of these complications. There was no
significant difference between the two groups.
The frequency of specific types of severe and moderate com-
plications, expressed as a percentage of the total number of com-
plications, was also compared to that reported in 315 patients in the
NACTN SCI Registry.22 For riluzole versus registry, the compar-
isons were the following: infection, including pneumonia (26 vs.
22%); pulmonary, including pulmonary embolism, respiratory
failure, lobar collapse, atelectasis, and pneumothorax (23 vs. 27%);
hematological, including DVT, anemia, thrombocytopenia, and
coagulopathy (12 vs. 15%); cardiac, including asystole, bradycar-
dia, arrhythmia, and shock (7 vs. 13%); neurological/psychiatric,
including neuropathic pain and depression and anxiety (15 vs. 7%);
GI/GU, including bleeding and bowel obstruction (11 vs. 9%); and
skin, including pressure sores (8 vs. 7%).
There were no SAEs attributable to riluzole. There were no
deaths.
Table 7. Cervical and Thoracic Injuries: Time to Riluzole Administration
Time window Minimum (h) 25th percentile (h) Median/mean (h) (SD) 75th percentile (h) Maximum (h)
Injury to admission
N = 36
0.7 1.5 2.3/3.0 (1.8) 4.2 7.0
Injury to riluzole
N = 36
3.7 6.9 8.5/8.7 (2.2) 10.6 12.1
SD, standard deviation.
Table 8. Cervical and Thoracic Injuries:
Riluzole Patientsa
Complications
No. of
complications
Infection: 19 complications (14 patients)
Urinary tract infection 10
Pneumonia 5
Staphylococcal infection of skin 2
Sepsisb 1
Infectious diarrhea 1
Pulmonary: 17 complications (11 patients)
Respiratory failure 7
Lobar collapse/atelectasis 3
Pneumothorax 2
Acute respiratory distress syndromeb 2
Pleural effusion 1
Bronchial obstruction mucus plug, syncopeb 1
Pulmonary embolusb 1
Neurological/psychiatric: 11 complications (10 patients)
Neuropathic pain 4
Depression 3
Anxiety 2
Agitation 1
Elevation of sensory levelb 1
Hematological: 9 complications (7 patients)
Deep venous thrombosisb 3
Thrombocytopenia 2
Neutropenia 1
Coagulopathy 1
Thrombophlebitis 1
Severe anemia 1
Gastrointestinal: 7 complications (5 patients)
Prolonged nausea/vomiting 3
Rectal hemorrhageb 1
Dysphagia 1
Anal fistula 1
Bowel obstructionb 1
Skin: 6 complications (4 patients)
Pressure-damaged skin areas other than sacral 3
Sacral decubiti 2
Rash: allergic reaction 1
Cardiovascular: 5 complications (5 patients)
Prolonged arrhythmia 2
Asystolic episodeb 1
Prolonged bradycardia ( < 50 bpm) 1
Prolonged shock (BP < 80 mmHg) 1
aSeventy-four severe and moderate medical complications and 12
serious adverse events within 30 days of admission in 36 patients.
bReported as a serious adverse event (total, N = 12).
bpm, beats per minute; BP, blood pressure.
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Safety: Elevation of liver enzymes and bilirubin
above the upper limit of normal
Liver enzymes and bilirubin were monitored on admission and
during administration of riluzole. On admission, elevated levels of
different liver enzymes and bilirubin were found in 9–37% of pa-
tients. Thirteen percent of patients had mild ( >ULN to 2.5 ·ULN)
or moderate ( > 2.5–5·ULN) elevations of alanine transferase
(ALT), 37% had mild or moderate elevations of aspartate trans-
aminase (AST), 11% had mild elevations of GGT, and 9% had mild
elevations of bilirubin (Table 10; Fig. 2). Some patients had ele-
vation of a single enzyme, whereas others had two or three enzymes
elevated.
During administration of riluzole, liver enzymes and bilirubin
were monitored on days 3, 7, 10, and 14. Incidence of elevation of
enzyme levels increased during administration of riluzole, with
increasing frequency in the second week of administration. Seventy
percent of patients had mild or moderate elevations of ALT and
63% of AST on at least one of the days of testing. One patient had
a borderline severe elevation of ALT (6 ·ULN; (severe defined
as > 5–20 ·ULN). Another patient had a borderline severe eleva-
tion of AST (5.5 ·ULN). These elevations returned to normal at 3
and 6 months. Fifty-three percent of patients had mild or moderate
elevations of GGT, and 1 patient had a borderline severe elevation
of GGT (7 ·ULN). Seventeen percent had mild or moderate ele-
vations of alkaline phosphatase (ALP). Fourteen percent had mild
or moderate elevation of bilirubin (Table 10; Fig. 2).
No patient had elevated bilirubin on day 14, the last day of
administration of riluzole. The appearance of an increased level of a
liver enzyme was not necessarily followed by a progressive in-
crease in the level of that enzyme. In many cases, the elevated
concentration had returned to a normal level at the next date of
testing. The elevation of one enzyme was not necessarily linked to
the elevation of another enzyme.
No relationship was found between the Cmax of riluzole and liver
enzyme levels.
Neurological outcome
Neurological outcome was assessed with ISNCSCI total motor
score progression, sensory score progression, impairment grade
conversion, and SCIM. Each measure was assessed separately for
cervical and thoracic injury cohorts and stratified by impairment
grades A, B, and C.
Cervical injuries: Progression of motor scores
from admission to 42, 90, and 180 days
A flow diagram of the subgroups of the riluzole and registry
cohorts, stratified as described above and the number of patients
with complete ISNCSCI motor data available for comparison on
the specified days after injury, is shown in Figure 1.
After withdrawal of 1 patient (C4 level of injury impairment
grade C, see above, ‘‘Patient withdrawal’’), there were 27 with
cervical injuries available for measurement of motor scores. The
impairment grades and numbers of these patients were A-12, B-8,
and C-7. Motor score outcomes in the riluzole-treated cohort were
compared with those in a matched cohort of patients drawn from the
NACTN SCI Registry (Table 4). The progression of the total motor
scores from admission to 42 days for the riluzole cohort, and to 90
and 180 days for the riluzole and registry cohorts, is shown in Table
11 and illustrated graphically in Figure 3. Table 11 shows the
Table 9. Cervical and Thoracic Injuries: Riluzole and Registry Patients: Incidence of Medical Complications
and p Values of Differences
Riluzole N = 36 Registry N = 36
System/category Patientsa Incidenceb Patientsa Incidenceb p value*
Infection 14 0.389 13 0.361 0.81
Pulmonary 11 0.306 16 0.444 0.22
Neuropsychiatric 10 0.278 8 0.222 0.59
Hematological 7 0.194 9 0.250 0.57
Cardiovascular 5 0.139 11 0.306 0.09
GI/GU 5 0.139 9 0.250 0.19
Skin 4 0.111 3 0.083 0.69
aNumber of patients with at least one complication of the specified system.
bIncidence of complications within 30 days of injury.
*Pearson’s chi-square test for comparing two proportions.
GI, gastrointestinal; GU, genitourinary.
Table 10. Cervical and Thoracic Injuries:
Liver Enzyme and Bilirubin Elevations
at Admission and during Riluzole Administrationa
ALT AST ALP GGT Bilirubin
N (%) N (%) N (%) N (%) N (%)
Admission before riluzole
Normal 27 (87) 20 (62) 32 (100) 25 (89) 29 (91)
Mildb 3 (10) 8 (25) 0 (0) 3 (11) 3 (9)
Moderatec 1 (3) 4 (12) 0 (0) 0 (0) 0 (0)
Severed 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total 31 (100) 32 (100) 32 (100) 28 (100) 32 (100)
While receiving riluzole
Normal 10 (28) 12 (33) 30 (83) 15 (44) 31 (86)
Mildb 15 (42) 16 (44) 5 (14) 13 (38) 4 (11)
Moderatec 10 (28) 7 (19) 1 (3) 5 (15) 1 (3)
Severed 1 (3) 1 (3) 0 (0) 1 (3) 0 (0)
Total 36 (100) 36 (100) 36 (100) 34 (100) 36 (100)
aSee Figure 2.
bMild: >ULN to 2.5·ULN.
cModerate: > 2.5–5·ULN.
dSevere: > 5–20·ULN.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP,
alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; ULN, upper
limit of normal.
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FIG. 2. Cervical and thoracic injuries: frequency of normal and elevated liver enzymes and bilirubin. See Table 10. ALT, alanine
transferase; AST, aspartate transamine; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; RZ, riluzole.
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Table 11. Cervical Injuries: Riluzole and Registry Patients
Riluzole
Admission N Admissiona mean (SD) 42-day mean (SD) Registry
A 10 16.8 (15.9) 24.0 (16.1)
B 8 16.4 (10.1) 44.5 (25.6)
C 7 30.3 (23.0) 64.4 (28.1)
All 25 20.4 (17.2) 41.9 (27.8)
Admission to 90 days N Admissionb mean (SD) 90-day mean (SD) N Admissiond mean (SD) 90-day mean (SD)
A 9 14.6 (9.3) 27.3 (26.3) 12 21.6 (14.2) 31.9 (19.9)
B 8 16.4 (10.1) 55.4 (28.1) 8 19.9 (9.2) 31.0 (22.9)
C 7 30.3 (23.0) 76.1 (18.8) 6 36.7 (13.0) 68.8 (18.1)
All 24 19.7 (15.7) 50.9 (31.5) 26 24.5 (13.9) 40.2 (25.4)
Admission to 180 days N Admissionc mean (SD) 180-day mean (SD) N Admissione mean (SD) 180-day mean (SD)
A 7 16.1 (8.7) 31.4 (29.6) 9 23.3 (13.8) 34.8 (20.8)
B 7 14.6 (9.4) 60.3 (24.6) 5 22.4 (11.1) 46.6 (32.5)
C 6 32.0 (24.5) 81.8 (23.9) 6 33.0 (13.9) 84.0 (12.3)
All 20 20.4 (16.6) 56.6 (32.5) 20 26.0 (13.4) 52.5 (30.3)
Sample size, mean, and standard deviation of motor scores at 42, 90, and 180 days are stratified by admission impairment grade (see Fig. 3). See
consort diagram, Figure 1, and graph, Figure 3.
aIncludes 25 riluzole patients with both an admission and 42-day motor score.
bIncludes 24 riluzole patients with both an admission and 90-day motor score.
cIncludes 20 riluzole patients with both an admission and 180-day motor score.
dIncludes 26 registry patients with both an admission and 90-day motor score.
eIncludes 20 registry patients with both an admission and 180-day motor score.
SD, standard deviation.
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FIG. 3. Cervical injuries: riluzole and registry patients. Progression of mean total motor score (and n patients available) at admission
and 42, 90, and 180 days, stratified by admission impairment grade. (A) All grades. (B) Grade A. (C) Grade B. (D) Grade C. See
Table 11.
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absolute motor scores at admission and at 90 and 180 days, strati-
fied by impairment grade on admission and for the cohort as a
whole. Table 12 shows the change in scores from admission to 90
and to 180 days, stratified by impairment grade on admission and
for the cohort as a whole.
Table 11 (upper panel) presents the progression of the mean total
motor score for 25 riluzole patients with cervical injuries from
admission to 42 days postinjury. The table includes only patients
with admission and 42-day scores. Patients are stratified by im-
pairment grades A, B, and C and by A +B +C, that is, the entire
group taken as a whole (all).
Ten patients (admission impairment grade A) progressed from
an admission mean motor score of 16.8 to 24.0 at 42 days, gaining
7.2 points and achieving 76% of the score of 31.4 reached at 180
days by 7 of these patients, as shown in the lowest panel of the table.
Eight patients (admission impairment grade B and motor score
of 16.4) progressed to a score of 44.5 at 42 days, a gain of 28.1
points and achieved 74% of the score of 60.3 reached at 180 days by
7 of these patients.
Seven patients (admission impairment grade C and motor score
of 30.3) progressed to a score of 64.4, a gain of 34.1 points, and
achieved 79% of the score of 81.8 reached at 180 days by 6 of these
patients.
For all grades, the group of 25 riluzole patients had a mean
admission motor score of 20.4, progressed to a score of 41.9 at 42
days, a gain of 21.5 points, and achieved 74% of the score of 56.6
reached at 180 days by 20 of these patients, as shown in the lowest
panel of the table.
The progression of motor scores to 90 and to 180 days for rilu-
zole patients and registry patients, stratified by impairment grades,
is shown in the middle and lowest panels, respectively, of Table 11
and is displayed graphically in Figure 3.
Table 11 (middle panel) compares the motor scores for 24 ri-
luzole and 26 registry patients at 90 days postinjury, stratified by
impairment grade. The table includes only patients with motor
scores for those dates. Data for both the riluzole and registry
groups, each taken as a whole (all), are shown in the lowest row of
the panel and are displayed graphically in Figure 3A. For the 90-
day comparison, the scores on admission were 19.7 for the riluzole
cohort and 24.5 for the registry cohort. At 90 days, the riluzole
cohort had progressed to a score of 50.9 and the registry cohort to a
score of 40.2.
The lowest panel shows the scores at 180 days. At 180 days, the
motor score for all patients was 56.6 for 20 riluzole patients and
52.5 for 20 registry patients.
The greatest gains in mean motor score occurred in grade B
patients. The score of riluzole B patients went from 16.4 on ad-
mission to 55.4 at 90 days. At 180 days, the score of 7 riluzole B
patients went from 14.6 to 60.3 (a 4.13-fold gain). The gain in
bilateral lower extremity motor score (LEMS) exceeded that of the
bilateral upper extremity motor score (UEMS). The gain in LEMS
for 8 patients from admission to 90 days was 25.9 points and for
UEMS, 13.1 points. The gain in LEMS for 7 patients from ad-
mission to 180 days was 29 points and for UEMS, 14.9 points.
The next-greatest gains were for C-grade patients, with a 2.45-
fold gain at 90 days and 2.56-fold gain at 180 days. Grade A patients
had the lowest gains (1.86-fold at 90 days and 1.95-fold at 180 days).
Table 12 presents the change of motor score and the riluzole
cohort-registry cohort difference in the gain of scores and p values.
The data are stratified by impairment grades and for the cohort as a
whole for patients with admission and 90-day scores and patients
with admission and 180-day scores.
For grade A patients, the riluzole-registry mean difference at 90
days was 2.4 points ( p= 0.787); for grade B patients, 27.9
( p= 0.037); for grade C patients, 13.7 ( p = 0.194). For the entire
cohort, the difference was 15.5 (significant at p= 0.021). The score
for the grade B patients contributed the largest effect toward the
significance value for the entire group.
At 180 days, the riluzole-registry difference for grade B patients
was 21.5 ( p= 0.208) and for grade C patients, - 1.2 ( p= 0.911).
For all patients, the difference was 9.8 ( p= 0.248).
Figure 4 presents a box-plot comparison of the gains in motor
scores from admission to 90 days for 24 riluzole patients and for 26
registry patients, as well as for 20 patients of each group at 180
days. Box plots show the median gain and the 75th and 25th per-
centiles and the maximum and minimum values for both groups.
The median is used rather than the mean because the data are
skewed toward higher motor score values, and thus a mean does not
adequately locate the center of the data. This is particularly true for
the 90-day gains. At 90 days, the median value was 23.5 for the
Table 12. Cervical Injuries: Riluzole and Registry Patients: Motor Score Mean Changes
from Admission to 90 Days and from Admission to 180 Days
Riluzole Registry Riluzole: registry
Admission AIS N 90-day change mean (SD) N N 90-day change mean (SD) difference mean p value*
A 9 12.7 (20.7) 12 12 10.3 (17.1) 2.4 0.787
B 8 39.0 (28.7) 8 8 11.1 (17.4) 27.9 0.037
C 7 45.8 (16.0) 7 6 32.1 (19.3) 13.7 0.194
Alla 24 31.2 (26.2) 27 26 15.7 (19.3) 15.5 0.021
Admission AIS N 180-day change mean (SD) N N 180-day change mean (SD)
Riluzole: registry
difference mean p value*
A 7 15.3 (9.3) 7 9 11.4 (17.2) 3.9 0.715
B 7 45.7 (10.8) 5 5 24.2 (24.8) 21.5 0.208
C 6 49.8 (8.4) 5 6 51.0 (9.7) –1.2 0.911
Allb 20 36.3 (28.5) 18 20 26.5 (24.0) 9.8 0.248
aIncludes all cases with both an admission and 90-day total motor score.
bIncludes all cases with both an admission and 180-day total motor score.
*Exact p values based on the nonparametric permutation test for two independent samples.
AIS, American Spinal Injury Association (ASIA) Impairment Scale; SD, standard deviation.
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riluzole group and 7 for the registry group. At 180 days, the median
value was 36 for the riluzole patients and 29.5 for the registry
patients. The distribution of the data indicates more robust motor
outcome in the riluzole patients.
No relationship was found between gain in motor score and time
from injury to administration of riluzole.
No differences were found in outcome motor scores between the
14 patients (cervical and thoracic) who received both MPSS and
riluzole and patients who received only riluzole.
Cervical injuries: Progression of sensory scores
Pin-prick scores were available at 90 days for 24 riluzole patients
and for 23 registry patients, as well as at 180 days for 20 riluzole
and 15 registry patients. Box plots of gain in pin-prick scores for
riluzole and for registry patients at 90 and 180 days are shown in
Figure 5 as an example of the changes that were observed for both
light touch and for pin-prick sensation. Pin-prick scores were 10
points higher for the riluzole patients than for the registry patients at
90 days and 9 points higher at 180 days for the riluzole patients than
for the registry patients, but the differences in gains were not sig-
nificant. The results for light touch were similar.
Cervical injuries: conversion of impairment grades
at 90 days and at 180 days
Table 13 shows the change in impairment grades from admission
to 90 days for 27 patients with cervical injuries and 26 matched
registry patients. Of 12 grade A riluzole patients, 6 (50%) remained
at A, 3 (25%) converted to B, 2 (17%) went to C, and 1 (8%) to D. In
contrast, of 12 grade A registry patients, 9 (75%) remained at A and
1 (8%) each converted to B, C, and D.
Of 8 grade B riluzole patients, 1 remained at B, 3 converted to C, and
4 converted to D. In contrast, of 8 grade B registry patients, 4 (50%)
remained at B, 3 (38%) converted to C, and 1 (12%) converted to D.
Of 7 grade C riluzole patients, 1 remained at C (14%), 5 (72%)
converted to D, and 1 (14%) converted to E. In contrast, of 5 reg-
istry patients, 3 (60%) remained at C and 2 (40%) converted to D.
Table 14 shows conversions at180 days for 20 patients in the
riluzole cohort and 20 in the registry cohort with impairment data.
The percentage of patients that converted to a more functional
grade continued to be higher in the riluzole than in the registry
cohort. The greatest positive effect was in grade B patients.
Cervical injuries: Spinal Cord Independence Measure
SCIM scores were available at 180 days for 20 riluzole patients
and for 14 registry patients. There was no significant difference in
the total score for the entire riluzole cohort, in comparison to the
registry cohort. Seven B grade patients, however, had a 17.8-point
mean advantage over 5 grade B registry patients.
Thoracic injuries
There were 8 thoracic injuries: 7 grade A and 1 grade B. At 180
days, the group exhibited a mean gain of 3 points in total motor
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FIG. 4. Cervical injuries: riluzole and registry patients. Box plots of gains in total motor score. (A) 90 days. (B) 180 days. max, min,
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score and a 5.2-point gain in pin-prick score. Three of the 7 grade A
patients converted to a more functional grade; 2 of the 7 matched
registry grade A patients converted to a more functional grade.
Discussion
Feasibility of riluzole as an acutely administered
therapy for spinal cord injury
The study demonstrates that it is feasible to screen, consent, and
enroll SCI patients in a clinical trial of drug therapy, obtain labo-
ratory and radiological data, and start pharmacological therapy
within 12 h of injury. This finding should provide encouragement
for further trials of therapies that must be applied very rapidly after
SCI.
Demographic and neurological characteristics
of the riluzole cohort
The patients enrolled in the present trial were representative of
the population of SCI admitted to NACTN center hospitals in the
distribution of injuries between cervical and thoracic locations and
in the distribution of their impairment grades. Cervical injuries
comprised 78% of the patients in the present study (Table 5), and
the ratio of cervical to thoracic injuries and their impairment grades
were similar in the NACTN SCI Registry. Therefore, there does not
appear to be selection bias of patients for the present trial.
Pharmacology of riluzole in spinal cord injury
It would be expected that for riluzole to have a therapeutic effect,
a threshold level of blood-plasma concentration must be reached
and that there is a therapeutic range of concentrations.
An aim of the present study was to determine whether an asso-
ciation could be observed between blood-plasma levels of riluzole
and motor outcome scores, with the object of determining a ther-
apeutic blood-plasma level of riluzole. The previously published
report of the pharmacology of riluzole in the patients in this phase I
trial indicated that on day 3 of administration, there was a 17-fold
difference in maximal concentration of riluzole between the lowest
and highest values (24–409 ng/mL) in different patients. The cause
of the variability in blood levels is likely to be, in part, the result of
differences in absorption of riluzole from the gut16 and, in part,
from variability in individual body mass index (Table 4). An at-
tempt was made to correlate Cmax and gain in motor and sensory
scores for all cervical injury patients as a group and for A, B, and C
subgroups. No significant correlation was found. However, there
was a positive correlation for grade B patients when extreme,
outlying motor score and Cmax values were censored. It is possible
that the low levels of plasma concentration of riluzole, in some
patients, did not reach a threshold for efficacy. Considering the
multiple factors that determine neurological outcome, it may be
difficult to achieve a correlation. Further analysis will be under-
taken in a phase II study with a larger number of patients in an
attempt to validate a therapeutic effect and determine a therapeutic
range of plasma concentration. If a therapeutic effect and range can
be established, monitoring of plasma levels and adjustment of the
enteral dose would be a rational approach to therapy.
The previous publication of the pharmacology of riluzole in SCI
reported on the finding of an increase in the clearance and distri-
bution of riluzole between the 3rd and 14th days of administration
that resulted in a lower plasma concentration on day 14. This
finding indicates that the changing physiology of the SCI patient
can affect the metabolism of drugs and emphasizes the importance
of monitoring changes in drug metabolism in SCI clinical trials for
evaluating safety and efficacy data. It is also another factor that
suggests the possible utility of monitoring blood levels of riluzole
to adjust dosage.
Safety of riluzole in spinal cord injury: Medical
complications and serious adverse events
The primary aim of the phase I trial was to determine the inci-
dence of medical complications and SAEs in SCI patients receiving
riluzole. The incidence and types of complications were similar in
the riluzole patients and in the comparison registry group and in the
larger NACTN SCI Registry.22 There were no SAEs attributable to
riluzole and no deaths. In the NACTN SCI Registry, mortality in
126 patients with impairment grade A was 8.7% (11 patients). The
Table 13. Cervical Injuries: Riluzole
and Registry Patients
Riluzole
Admission
90 days
A B C D E
Grade N = 27 N (%) N (%) N (%) N (%) N (%)
A 12 6 (50) 3 (25) 2 (17) 1 (8)
B 8 1 (13) 3 (37) 4 (50)
C 7 1 (14) 5 (72) 1 (14)
Registry
Admission
90 days
A B C D E
Grade N = 26 N (%) N (%) N (%) N (%) N (%)
A 12 9 (75) 1 (8) 1 (8) 1 (8)
B 8 4 (50) 3 (38) 1 (12)
C 6 3 (50) 3 (50)
Conversions of impairment grades at 90 days.
Table 14. Cervical Injuries: Riluzole
and Registry Patients
Riluzole
Admission
180 days
A B C D E
Grades N = 20 N (%) N (%) N (%) N (%) N (%)
A 7 5 (71) 1 (14) 0 (0) 1 (14) 0 (0)
B 7 2 (29) 5 (71) 0 (0)
C 6 1 (17) 4 (64) 1 (17)
Registry
Admission
180 days
A B C D E
Grades N = 20 N (%) N (%) N (%) N (%) N (%)
A 9 7 (78) 1 (11) 0 (0) 1 (11) 0 (0)
B 5 2 (40) 1 (20) 2 (40) 0 (0)
C 6 0 (0) 6 (100) 0 (0)
Conversions of impairment grades at 180 days.
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leading causes of death were cardiac (n= 4), pulmonary (n = 4), and
multi-organ failure (n = 2). If the same mortality rate occurred
among the 19 grade A patients in the present trial, an average
mortality of 1.65 patients would be expected.
Safety: Effects on liver enzymes
Elevations of ALT and of AST are considered to be indicators of
drug-induced damage to liver cells. Elevation of GGT is a less-
specific indictor of drug-induced damage to the liver. Elevation of
ALP is considered to be primarily an indicator of obstruction of the
bile duct. Elevation of liver enzymes has been reported in patients
with ALS undergoing treatment with riluzole.17 Elevation of liver
enzymes has been reported to occur acutely in patients with SCI23
and in animal models of SCI, possibly resulting from impairment of
blood flow to the liver.24,25 In the present study, riluzole adminis-
tration in SCI patients was associated with a mild to moderate
elevation of blood levels of ALT, AST, GGT, ALP, and bilirubin, to
a varying degree for each of these markers of liver function. Ele-
vations of ALT, AST, and GGT that reached the lower levels of a
severe elevation ( > 5–20 ·ULN) occurred on one occasion in each
of 1 patient for each of these enzymes. Enzyme elevations were
transient and bilirubin levels were normal on the last day of riluzole
administration. Mild and moderate elevation of ALT and AST in
SCI patients, as reported by Shepard and Bracken,23 was confirmed
to occur within the first day of injury before administration of
riluzole.
Neurological outcomes: Cervical injuries, motor scores
As a phase I trial whose primary aims were determining the PK
and safety of riluzole, and without a concomitant control group, the
trial was not designed or powered to detect significant changes in
neurological outcome. Nevertheless, a trend was observed of a
more robust outcome in riluzole-treated patients.
Comparison can be made with the results of the recently pub-
lished phase II placebo-controlled, randomized trial of minocycline
in acute SCI.26 Minocycline administration was associated with a
14-point gain in motor score over placebo, and motor score re-
covery substantially reached a plateau after 3 months. In the present
phase I trial, a gain of 15.5 points was found for the riluzole group
of 24 patients over the comparison registry group of 26 patients. It
is difficult to precisely determine the comparability of the mino-
cycline and the riluzole treatment groups and of the registry com-
parison and the placebo control group with respect to the
anatomical levels of injury, distribution of impairment scores, and
numbers of patients. Putting the question of comparability aside,
Figure 3 of the minocycline article, showing graphs of motor gains
of minocycline and placebo patients, shows, for minocycline pa-
tients, a gain from admission to 190 days of approximately 28
points, and for placebo, a gain of approximately 14 points. This
gain is comparable to the gain at 180 days in the present phase I
riluzole trial of 31.2 points for 24 riluzole patients and of 15.7
points for 26 registry patients.
In the minocycline trial in patients with cervical injuries, LEMS
had greater gains than UEMS. In the present study, the same ob-
servation was made for grade B patients with cervical injuries who
received riluzole.
Comparison of gains in UEMS can also be made with a recent
report of the extent of spontaneous motor recovery after traumatic
cervical sensorimotor complete SCI.27 Analysis of the Sygen trial
and the European Multi-Center Study about SCI (EM-SCI) data-
bases found a 10–11-point gain in UEMS at 1 year. The riluzole
grade B patients, not as severely impaired as grade A patients,
achieved a UEMS gain of 14.9 points at 180 days and a LEMS gain
of 29 points.
Cervical injuries: Progression of sensory scores
In the minocycline trial, cervical motor-incomplete patients had
pin-prick scores that were 14 points greater than placebo patients.26
In the riluzole patients, complete and incomplete injuries in the
present study had, at 180 days, a gain of 9 points over the registry
patients.
Cervical injuries: conversion of impairment grades
The most robust conversions were exhibited by grade B patients.
At 90 days, 87% of 8 grade B riluzole patients converted to a more
functional grade, compared to 50% of 8 grade B registry patients.
At 180 days, all 7 (100%) of grade B riluzole patients had pro-
gressed to a more functional grade, compared to 3 (60%) of 5
registry patients.
These findings can be compared to data in the recent publication
of motor recovery of cervical SCI from the National Spinal Cord
Injury Statistical Center (NSCISC) database. For grade B patients,
from a baseline of 7 days or less, to 1 year, 34% remained at grade B
and 67% converted to C (30%) and D (37%).28
Conversions of grade A patients were not as robust, and rates for
riluzole and registry patients were comparable to those reported in
the EM-SCI database: For grade A patients assessed within 2 weeks
of injury with a final assessment at 1 year, 32% converted to a more
functional grade.29 These figures are in agreement with the
NSCISC database figure of 30% conversion at 1 year28 and cor-
respond in the present phase I study to the conversion rate for 7
grade A riluzole patients of 29% at 180 days.
It should be noted, in making comparisons with these two
studies,28,29 that their baseline measurements were made within 1
week of injury in one study and within 2 weeks in the other. In the
present study, baseline assessment of impairment grade was made
within 12 h of injury. It is well recognized that within such a group
of patients, spontaneous improvement may occur rapidly, which
would result in a different classification of some of the patients in
the group if the assessment had been made at 72 h. However, the
registry group was also assessed within 12 h and should be an ap-
propriate comparison group.
Cervical injuries: The Spinal Cord Independence
Measure
At 180 days, there was no significant difference between the
SCIM scores of the riluzole and registry groups, although there was
a trend for better scores for grade B patients.
Improvement in functional outcome is, of course, the desired
goal of therapy. Further detailed study of SCIM and other func-
tional outcome measures in a phase II trial is warranted.
Thoracic injuries
The 8 thoracic injuries in the present study were all motor
complete. On admission, 1 patient had sacral sensation. There was
minimal improvement of motor and sensory score in this group of
patients. A recent report of the neurological outcomes of 399 tho-
racic complete patients in the EM-SCI database found minimal
motor and sensory improvement in this group of severely injured
patients.30 Motor improvement occurred predominantly in patients
with low thoracic injury. There were only two such individuals in
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the present riluzole study. Therefore, a therapeutic effect of riluzole
might be detected in a larger number of low thoracic injuries and in
patients who are grade B or C.
Limitations of the study
The trial was open label and the patients and examiners were
aware of the treatment, factors that might result in a positive bias for
riluzole treatment.
The outcomes of the patients receiving riluzole were com-
pared with a recent historical group of patients in the NACTN
SCI registry and not with a contemporaneous control group, as
would occur in a phase II trial. However, the comparison registry
group used to evaluate outcomes was treated at NACTN hospi-
tals operating under the same standard-of-care protocol, and
many riluzole and registry patients were evaluated by the same
clinical teams, which may have reduced the variability of scoring
of outcome measures.
Factors other than treatment with riluzole may have influenced
neurological outcome. The very short time from injury to ED ad-
mission and supportive medical care and from injury to surgical
decompression and stabilization for both the riluzole and registry
patients may have had a therapeutic effect, when compared to
historical studies performed at earlier times, when the incidence of
decompression or stabilization surgery was not as great or carried
out as urgently.
The number of patients was small, particularly when stratified by
impairment scores. As commonly observed in longitudinal studies of
acute SCI, the number of patients available for examination de-
creased as patients completed inpatient rehabilitation and returned to
their homes or to a care facility far from a NACTN center: Despite
strenuous efforts to obtain data from all patients unable to return to a
center for examination, 3 of the 27 cervical injury patients who
completed the 14-day course of riluzole treatment were unavailable
for examination at 90 days, and an additional 4 were unavailable at
180 days, leaving 24 riluzole patients for analysis at 90 days and 20 at
180 days. The variability of neurological outcomes of SCI patients is
great, particularly of grade C patients, and in a small sample, even 1
or 2 patients with extreme scores can bias the results.
Conclusion
Riluzole administered enterally within 12 h of SCI was well tol-
erated. There were no SAEs attributable to riluzole. Bearing in mind
the limitations of the study, the exploratory pilot data suggest that
riluzole may have a beneficial effect on motor outcome in cervical
SCI that was manifest at 90 days postinjury. Improvement in lower
extremity motor score appeared to be the primary effect. Further
study of the PK, safety, and effects of riluzole on neurological out-
come in acute traumatic SCI will be carried out in a phase II trial.
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